Diplomat Announces 2nd Quarter Financial Results

08/07/2017

2nd Quarter Revenue Increased 3.5%, Net Income Attributable to Diplomat of $3.6 Million, Adjusted EBITDA of $25.2 Million

FLINT, Mich., Aug. 7, 2017 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced financial results for the quarter ended June 30, 2017.  All comparisons, unless otherwise noted, are to the quarter ended June 30, 2016.

Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.)

Second Quarter 2017 Highlights include:

  • Revenue of $1,126 million, compared to $1,089 million, an increase of 3.5%
  • Total prescriptions dispensed of 220,000, compared to 241,000
  • Gross margin of 7.5% versus 7.6%
    • Gross profit per prescription dispensed of $371, compared to $339
  • Net income attributable to Diplomat of $3.6 million, compared to $8.5 million
  • Adjusted EBITDA of $25.2 million, compared to $29.6 million
    • Adjusted EBITDA margin of 2.2% versus 2.7%
  • EPS of $0.05 per diluted common share versus $0.13
    • Adjusted EPS of $0.25 versus $0.23

Phil Hagerman, CEO and Chairman of Diplomat, commented, "I'm very pleased with our solid second quarter results, which saw continued strength in oncology and infusion, up 25% and 20% year over year, respectively.  In the first half of 2017, a transition year for Diplomat, we have made promising strides in our, higher margin, tuck-in acquisition strategy in infusion, as well as with our managed care strategy.  In addition, we are seeing customers start to embrace our expanded service division. Finally, I'm thrilled to announce that Joel Saban has joined us as President of Diplomat, bringing years of industry experience, which I believe will be a tremendous asset to our company."

Second Quarter Financial Summary:

Revenue for the second quarter of 2017 was $1,126 million, compared to $1,089 million in the second quarter of 2016, an increase of $38 million or 3.5%.  The increase was driven by approximately $83 million of revenue from our acquisitions, approximately $63 million from the impact of manufacturer price increases, and approximately $32 million from drugs that were new in the past year.  These increases were partially offset by a decrease due to contracts that were not renewed in 2017 as well as a decrease in the demand for hepatitis C drugs versus the prior year period.  Our revenue increase year over year, excluding the impact of the contract losses was approximately $160 million or 15%. 

Gross profit in the second quarter of 2017 was $84.8 million and generated a 7.5% gross margin, compared to $83.3 million and 7.6% in the second quarter of 2016.  The gross margin decline in the quarter was primarily due to an increase in accrued direct and indirect remuneration ("DIR") fees versus what was accrued in the second quarter of 2016. 

Selling, general, and administrative expenses ("SG&A") for the second quarter of 2017 were $80.0 million, an increase of $10.6 million, compared to $69.4 million in the second quarter of 2016.  Of this change, $7.2 million related to employee cost, including employee cost for our acquired entities.  The increased employee expense was attributable to the growth in our infusion and oncology business which is more clinically and administratively complex.  Also contributing to the SG&A expense increase was a $3.1 million increase in amortization expense from definite-lived intangible assets associated with our acquired entities.  We also experienced increases in other SG&A; including freight, insurance, and other miscellaneous expenses.  As a percentage of revenue, SG&A was 7.1% for the three months ended June 30, 2017, compared to 6.4% in the prior year period.  This increase is primarily attributable to the increase in acquisition related amortization and the increased operating complexity associated with both our acquisitions and new drugs.

Net income attributable to Diplomat for the second quarter of 2017 was $3.6 million compared to $8.5 million in the second quarter of 2016.  This decrease was primarily driven by the revenue, gross profit, and SG&A explanations above, partially offset by a $4.7 million change in income taxes. Adjusted EBITDA for the second quarter of 2017 was $25.2 million compared to $29.6 million in the second quarter of 2016, a decrease of $4.5 million

Earnings per share for the second quarter of 2017 was $0.05 per basic/diluted common share, compared to $0.13 per basic/diluted common share for the second quarter of 2016.  Diluted non-GAAP adjusted earnings per share ("Adjusted EPS") was $0.25 in the second quarter of this year compared to $0.23 in the second quarter of 2016.   

2017 Financial Outlook

For the full-year 2017, we are updating our previous financial guidance:

  • Revenue between $4.3 and $4.6 billion, versus the previous range of $4.3 and $4.7 billion
  • Net income attributable to Diplomat between $10 and $16 million, versus the previous range of $6.5 and $15.5 million
  • Adjusted EBITDA between $97 and $103 million, versus the previous range of $95 and $103 million
  • Diluted EPS between $0.15 and $0.23, versus the previous range of $0.09 and $0.23  
  • Adjusted EPS between $0.71 and $0.79, versus the previous range of $0.54 and $0.70

Our EPS and Adjusted EPS expectations assume approximately 68,600,000 weighted average common shares outstanding on a diluted basis and a tax rate of 26%, versus the previous tax rate of 35% and 40% for the high and low of the range respectively, for the full year 2017, which could differ materially. 

Earnings Conference Call Information

As previously announced, the Company will hold a conference call to discuss its second quarter performance this evening, August 7, 2017, at 5:00 p.m. Eastern Time.  Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 877-201-0168 (or 647-788-4901 for international callers) and referencing participant code 51641230 approximately 15 minutes prior to the call.  A live webcast and audio file of the conference call will be available on the investor relations section of the Company's website for approximately 90 days at ir.diplomat.is.

About Diplomat

Diplomat (NYSE: DPLO) is the nation's largest independent provider of specialty pharmacy services—helping patients and providers in all 50 states. The company offers medication management programs for people with complex chronic diseases and delivers unique solutions for manufacturers, hospitals, payors, providers, and more. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: "Take good care of patients and the rest falls into place." Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit diplomat.is.

Non-GAAP Information

Adjusted EPS adds back, net of income taxes, the impact of all merger and acquisition related expenses, including amortization of intangible assets, the change in fair value of contingent consideration, as well as transaction-related costs.  We exclude merger and acquisition-related expenses from Adjusted EPS because we believe the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations and such expenses can vary significantly between periods as a result of new acquisitions, full amortization of previously acquired intangible assets, or ultimate realization of contingent consideration.  Investors should note that acquisitions, once consummated, contribute to revenue in the periods presented as well as future periods and should also note that amortization and contingent consideration expenses may recur in future periods.  A reconciliation of Adjusted EPS, a non-GAAP measure, to EPS as prepared in accordance with accounting principles generally accepted in the United States ("GAAP") can be found below.

We define Adjusted EBITDA as net income (loss) attributable to Diplomat before interest expense, income taxes, depreciation and amortization, share-based compensation, change in fair value of contingent consideration and other merger and acquisition-related expenses, restructuring and impairment charges, and certain other items that we do not consider indicative of our ongoing operating performance (which are itemized below in the reconciliation to net income (loss) attributable to Diplomat).  Adjusted EBITDA is not in accordance with, or an alternative to, GAAP.  In addition, this non‑GAAP measure is not based on any comprehensive set of accounting rules or principles.  You should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in the presentation, and we do not infer that our future results will be unaffected by unusual or non-recurring items. 

We consider Adjusted EBITDA and Adjusted EPS to be supplemental measures of our operating performance.  We present Adjusted EBITDA and Adjusted EPS because they are used by our Board of Directors and management to evaluate our operating performance.  Adjusted EBITDA is also used as a factor in determining incentive compensation, for budgetary planning and forecasting overall financial and operational expectations, for identifying underlying trends, and for evaluating the effectiveness of our business strategies.  Further, we believe they assist us, as well as investors, in comparing performance from period-to-period on a consistent basis.  Other companies in our industry may calculate Adjusted EBITDA and Adjusted EPS differently than we do and these calculations may not be comparable to our Adjusted EBITDA and Adjusted EPS metrics.  A reconciliation of Adjusted EBITDA, a non-GAAP measure, to net income (loss) attributable to Diplomat can be found below.

Forward Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance, and include Diplomat's expectations regarding revenues, net income (loss) attributable to Diplomat, Adjusted EBITDA, EPS, Adjusted EPS, market share, the performance of acquisitions and growth strategies.  The forward-looking statements contained in this press release are based on management's good-faith belief and reasonable judgment based on current information, and these statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements.  These risks and uncertainties include: our ability to adapt to changes or trends within the specialty pharmacy industry; significant and increasing pricing pressure from third-party payors; the amount of direct and indirect remuneration fees, as well as the timing of assessing such fees and the non-transparent methodology used to calculate such fees; the outcome of material legal proceedings related to direct and indirect remuneration fees; our relationships with key pharmaceutical manufacturers; bad publicity about, or market withdrawal of, specialty drugs we dispense; a significant increase in competition from a variety of companies in the health care industry; our ability to expand the number of specialty drugs we dispense and related services; maintaining existing patients; revenue concentration of the top specialty drugs we dispense; our ability to maintain relationships with a specified wholesaler and two pharmaceutical manufacturers or other pharmaceutical manufacturers that become material to our business over time; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to effectively execute our acquisition strategy or successfully integrate acquired businesses; dependence on our senior management and key employees and managing recent turnover among key employees; potential disruption to our workforce and operations due to recent cost savings and restructuring initiatives; and the additional factors set forth in "Risk Factors" in Diplomat's Annual Report on Form 10-K for the year ended December 31, 2016 and in subsequent reports filed with or furnished to the Securities and Exchange Commission.  Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments, or otherwise.

INVESTOR CONTACT:
Bob East, Westwicke Partners 
443-213-0500 | Diplomat@westwicke.com

 

DIPLOMAT PHARMACY, INC.

Condensed Consolidated Balance Sheets (Unaudited)

(dollars in thousands)




June 30,


December 31,

ASSETS


2017


2016

Current assets:





   Cash and equivalents

$

7,804

$

7,953

   Accounts receivable, net


279,604


275,568

   Inventories


178,131


215,351

   Prepaid expenses and other current assets


10,477


6,235

                    Total current assets


476,016


505,107

Property and equipment, net


20,963


20,372

Capitalized software for internal use, net


42,953


50,247

Goodwill


358,178


316,616

Definite-lived intangible assets, net


195,100


199,862

Deferred income taxes


5,031


6,010

Other noncurrent assets


1,081


1,040

                    Total assets

$

1,099,322

$

1,099,254






LIABILITIES AND SHAREHOLDERS' EQUITY





Current liabilities:





   Accounts payable

$

307,718

$

320,684

   Borrowings on line of credit


2,521


39,255

   Short-term debt, including current portion of long-term debt


10,875


7,500

   Accrued expenses:





        Compensation and benefits


6,511


5,674

        Other


12,792


12,233

                  Total current liabilities


340,417


385,346

Long-term debt, less current portion


119,006


100,184

Contingent consideration


4,365


-

                  Total liabilities


463,788


485,530

Commitments and contingencies





Shareholders' equity:





   Preferred stock (10,000,000 shares authorized; none issued and outstanding)


-


-

   Common stock (no par value, 590,000,000 shares authorized; 68,017,230 and 66,764,999





               shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively)


515,820


503,828

   Additional paid-in capital


35,372


33,268

   Retained earnings


84,264


76,306

   Total Diplomat Pharmacy shareholders' equity


635,456


613,402

Noncontrolling interests


78


322

                  Total shareholders' equity


635,534


613,724

                  Total liabilities and shareholders' equity

$

1,099,322

$

1,099,254

 

 

 

DIPLOMAT PHARMACY, INC.

Condensed Consolidated Statements of Operations (Unaudited)

(dollars in thousands, except per share amounts)

























































Three Months Ended



Six Months Ended









June 30,



June 30,









2017


2016



2017


2016

Net sales




$

1,126,464

$

1,088,506


$

2,205,204

$

2,084,376

Cost of goods sold


(1,041,630)


(1,005,236)



(2,035,321)


(1,921,868)



Gross profit


84,834


83,270



169,883


162,508

Selling, general and administrative expenses


(79,991)


(69,416)



(156,492)


(123,610)



Income from operations


4,843


13,854



13,391


38,898

Other (expense) income:











Interest expense


(1,931)


(1,521)



(3,980)


(2,956)


Other





34


105



66


213

Total other expense


(1,897)


(1,416)



(3,914)


(2,743)



Income before income taxes


2,946


12,438



9,477


36,155

Income tax benefit (expense)


544


(4,145)



(1,763)


(12,679)



Net income


3,490


8,293



7,714


23,476

Less: net loss attributable to noncontrolling interest


(101)


(241)



(244)


(487)

Net income attributable to Diplomat Pharmacy, Inc.

$

3,591

$

8,534


$

7,958

$

23,963

















Net income per common share:










Basic





$

0.05

$

0.13


$

0.12

$

0.37

Diluted





$

0.05

$

0.13


$

0.12

$

0.35

















Weighted average common shares outstanding:










Basic






67,528,151


66,085,149



67,209,280


65,312,155

Diluted






68,211,882


68,034,392



67,997,929


67,939,665

 

 

DIPLOMAT PHARMACY, INC.

Condensed Consolidated Statements of Cash Flows (Unaudited)

(dollars in thousands)































Six Months Ended June 30,









2017


2016

Cash flows from operating activities:






Net income


$

7,714

$

23,476


Adjustments to reconcile net income to net cash provided by operating activities:






     Depreciation and amortization


31,935


22,389


     Net provision for doubtful accounts


5,401


4,010


     Share-based compensation expense


3,798


3,152


     Deferred income tax expense


979


11,178


     Amortization of debt issuance costs


595


581


     Changes in fair values of contingent consideration


-


(8,922)


     Contingent consideration payment


-


(382)


     Other


6


1


     Changes in operating assets and liabilities, net of business acquisitions:






          Accounts receivable


(3,024)


(49,246)


          Inventories


37,179


(11,358)


          Accounts payable


(14,353)


52,878


          Other assets and liabilities


(2,977)


(1,808)



Net cash provided by operating activities


67,253


45,949

Cash flows from investing activities:






Payments to acquire businesses, net of cash acquired


(53,571)


(69,072)


Expenditures for capitalized software for internal use


(2,459)


(7,349)


Expenditures for property and equipment


(2,289)


(3,705)


Other


(43)


1



Net cash used in investing activities


(58,362)


(80,125)

Cash flows from financing activities:






Net (payments on) proceeds from line of credit


(36,734)


17,057


Proceeds from long-term debt


25,000


-


Payments on long-term debt


(3,313)


(3,000)


Proceeds from issuance of stock upon stock option exercises


6,007


1,203


Contingent consideration payment


-


(722)


Payments of debt issuance costs


-


(56)



Net cash (used in) provided by financing activities


(9,040)


14,482



Net increase (decrease) in cash and equivalents


(149)


(19,694)

Cash and equivalents at beginning of period


7,953


27,600

Cash and equivalents at end of period

$

7,804

$

7,906

Supplemental disclosures of cash flow information:






Cash paid for income taxes

$

4,458

$

401


Cash paid for interest


3,386


2,318

 

 

 

Adjusted EBITDA

The table below presents a reconciliation of net income attributable to Diplomat Pharmacy, Inc. to Adjusted EBITDA for the periods indicated.


For the three months ended June 30,


For the six months ended June 30,


2017


2016


2017


2016


(dollars in thousands) (unaudited)

Net income attributable to Diplomat Pharmacy, Inc.

$                     3,591


$                     8,534


$                      7,958


$                    23,963

Depreciation and amortization

16,538


12,271


31,935


22,389

Interest expense

1,931


1,521


3,980


2,956

Income tax (benefit) expense

(544)


4,145


1,763


12,679

EBITDA

$                   21,516


$                   26,471


$                    45,636


$                    61,987









Contingent consideration and other merger and acquisition expense

$                        569


$                     1,103


$                      1,117


$                    (7,326)

Share-based compensation expense

2,826


1,649


3,798


3,152

Employer payroll taxes - option repurchases and exercises

100


28


185


71

Severance and related fees

40


-


702


-

Other items

116


392


544


779

Adjusted EBITDA

$                   25,167


$                   29,643


$                    51,982


$                    58,663

 

Adjusted EPS (diluted)

Below is a reconciliation of net income attributable to Diplomat Pharmacy, Inc. per diluted share to Adjusted EPS for the periods indicated. 


For the three months ended June 30,


For the six months ended June 30,


2017


2016


2017


2016


(dollars in thousands, except per share amounts) (unaudited)

Net income attributable to Diplomat Pharmacy, Inc.

$                     3,591


$                     8,534


$                     7,958


$                  23,963

Amortization of acquisition-related intangible assets

12,944


9,818


25,265


18,502

Contingent consideration and other merger and acquisition expense

569


1,103


1,117


(7,326)

Income tax impact of adjustments

(362)


(3,639)


(4,909)


(3,731)

Adjusted non-GAAP net income

$                  16,742


$                  15,816


$                  29,431


$                  31,408









Net income attributable to Diplomat Pharmacy, Inc.

$                       0.05


$                       0.13


$                       0.12


$                       0.35

Amortization of acquisition-related intangible assets

0.19


0.14


0.37


0.27

Contingent consideration and other merger and acquisition expense

0.01


0.02


0.02


(0.11)

Income tax impact of adjustments

(0.01)


(0.06)


(0.08)


(0.06)

Adjusted EPS

$                       0.25


$                       0.23


$                       0.43


$                       0.46

















Weighted average common shares outstanding:








Diluted

68,211,882


68,034,392


67,997,929


67,939,665

 

2017 Full Year Guidance: GAAP to Non-GAAP Reconciliation

The tables below present a reconciliation of net income attributable to Diplomat Pharmacy, Inc. to Adjusted EBITDA and net income attributable to Diplomat Pharmacy, Inc. per diluted share to Adjusted EPS for the year ended December 31, 2017.

Reconciliation of GAAP to Adjusted EBITDA

(dollars in thousands) (unaudited)


 Range 


Low


High

Net income attributable to Diplomat Pharmacy, Inc.

$            10,000


$            16,000

Depreciation and amortization

64,660


64,352

Interest expense

7,299


6,999

Income tax expense 

3,398


5,506

EBITDA

$            85,357


$            92,857





Contingent consideration and other merger and acquisition expense 

$              2,517


$              2,017

Share-based compensation expense

7,242


6,642

Employer payroll taxes - option repurchases and exercises

338


238

Severance and related fees

1,002


702

Other items

544


544

Adjusted EBITDA

$            97,000


$          103,000













Reconciliation of GAAP to Adjusted Net Income and Adjusted EPS

(dollars in thousands, except per share amounts) (unaudited)


 Range 


Low


High

Net income attributable to Diplomat Pharmacy, Inc.

$            10,000


$            16,000

Amortization of acquisition-related intangible assets

49,813


49,813

Contingent consideration and other merger and acquisition expense 

2,517


2,017

Income tax impact of adjustments 

(13,606)


(13,476)

Adjusted non-GAAP net income

$            48,724


$            54,354





Net income attributable to Diplomat Pharmacy, Inc.

0.15


0.23

Amortization of acquisition-related intangible assets

0.73


0.73

Contingent consideration and other merger and acquisition expense

0.04


0.03

Income tax impact of adjustments

(0.21)


(0.20)

Adjusted EPS

$                0.71


$                0.79





 

View original content with multimedia:http://www.prnewswire.com/news-releases/diplomat-announces-2nd-quarter-financial-results-300500561.html

SOURCE Diplomat Pharmacy, Inc.

NYSE: DPLO

+0.16 +0.75% $ 21.39 Volume: 320,864 Common Stock | 20 minute delay October 20, 2017

Investor Contact

Asher S. Dewhurst

Investor Relations,
Westwicke Partners, LLC.
diplomat@westwicke.com

Phone: 443.213.0500

Email Now